Oncodrivers in Advanced or Metastatic NSCLC: Current and Future Standards of Care

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.

Panelists discuss individualized treatment selection based on age, comorbidities, and patient preferences in ALK-positive lung cancer.

Panelists discuss the biology and clinical implications of BRAF mutations in non–small cell lung cancer (NSCLC).

Panelists discuss evolving treatment approaches for BRAF-mutated metastatic lung cancer and their clinical impact.

Panelists discuss combination targeted approaches for managing BRAF-mutated lung cancer and their impact on disease durability.

Panelists discuss the latest trial results supporting dual-pathway inhibition in BRAF-mutated metastatic lung cancer.

Panelists discuss treatment selection, resistance challenges, and future directions in managing BRAF-mutated lung cancer.